212 related articles for article (PubMed ID: 8098254)
1. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease.
Kastner A; Hirsch EC; Agid Y; Javoy-Agid F
Brain Res; 1993 Mar; 606(2):341-5. PubMed ID: 8098254
[TBL] [Abstract][Full Text] [Related]
2. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study.
Javoy-Agid F; Hirsch EC; Dumas S; Duyckaerts C; Mallet J; Agid Y
Neuroscience; 1990; 38(1):245-53. PubMed ID: 1979431
[TBL] [Abstract][Full Text] [Related]
3. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
[TBL] [Abstract][Full Text] [Related]
4. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study.
Kingsbury AE; Marsden CD; Foster OJ
Mov Disord; 1999 Mar; 14(2):206-18. PubMed ID: 10091611
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease.
Kastner A; Hirsch EC; Herrero MT; Javoy-Agid F; Agid Y
J Neurochem; 1993 Sep; 61(3):1024-34. PubMed ID: 8103078
[TBL] [Abstract][Full Text] [Related]
6. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
Wang X; Yang HA; Wang XN; Du YF
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
[TBL] [Abstract][Full Text] [Related]
7. Lesions of nigrostriatal pathway reduce expression of tyrosine hydroxylase gene in residual dopaminergic neurons of substantia nigra.
Shirao T; Evinger MJ; Iacovitti L; Reis DJ
Neurosci Lett; 1992 Jul; 141(2):208-12. PubMed ID: 1359468
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine hydroxylase mRNA in the dopaminergic neurons of young adult and aged mice by in situ hybridization.
Gupta M; Stoler MH; Fossom LH; Tank AW
Neurosci Lett; 1990 Oct; 119(1):49-52. PubMed ID: 1982959
[TBL] [Abstract][Full Text] [Related]
10. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
11. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
12. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra.
Chu Y; Kompoliti K; Cochran EJ; Mufson EJ; Kordower JH
J Comp Neurol; 2002 Aug; 450(3):203-14. PubMed ID: 12209851
[TBL] [Abstract][Full Text] [Related]
13. Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain.
Blanchard V; Chritin M; Vyas S; Savasta M; Feuerstein C; Agid Y; Javoy-Agid F; Raisman-Vozari R
J Neurochem; 1995 Apr; 64(4):1669-79. PubMed ID: 7891094
[TBL] [Abstract][Full Text] [Related]
14. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
[TBL] [Abstract][Full Text] [Related]
15. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia.
Galter D; Buervenich S; Carmine A; Anvret M; Olson L
Neurobiol Dis; 2003 Dec; 14(3):637-47. PubMed ID: 14678778
[TBL] [Abstract][Full Text] [Related]
16. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies.
Kordower JH; Rosenstein JM; Collier TJ; Burke MA; Chen EY; Li JM; Martel L; Levey AE; Mufson EJ; Freeman TB; Olanow CW
J Comp Neurol; 1996 Jun; 370(2):203-30. PubMed ID: 8808731
[TBL] [Abstract][Full Text] [Related]
17. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
18. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.
Nagatsu T; Sawada M
J Neural Transm Suppl; 2007; (72):113-20. PubMed ID: 17982884
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
20. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.
McMillan PJ; White SS; Franklin A; Greenup JL; Leverenz JB; Raskind MA; Szot P
Brain Res; 2011 Feb; 1373():240-52. PubMed ID: 21147074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
